A Biotechnology Firm
Leading The Translational Glycobiology Research
GlycoMantra is a biologics company developing novel therapeutics for unmet medical needs in metastatic castration-resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes.
Galectin-3 is involved in cancer progression and metastasis of many solid tumors not only by mediating neo-angiogenesis and cancer cell homotypic/heterotypic adhesions, but also by suppressing host immunity. Click here to learn more…
Current focus of our research is on the galectin-3, a member of the beta-galactoside-binding lectin family. Click here to learn more…
Our experienced and dedicated team is ready to provide wide range of research services from simple one step protein or antibody purification…Click here to learn more about our team…
Who We Are/Our Interest
We are a start-up biotechnology firm leading the translational glycobiology research and interested in the development of carbohydrate-based therapeutics of cancer, fibrosis, and diabetes. Animal cell surfaces are covered with carbohydrates and proteins. In normal scenario, these components mediate interactions between two cells or between the cell and the extra-cellular matrix components. However, abnormal protein-carbohydrate interactions and associated cell signaling can lead to many diseases such as cancer, fibrosis, and diabetes. Our goal is to develop high affinity carbohydrate-based drugs that counteract these abnormal interactions